Enzo Biochem

These products are designed for the diagnosis of and/or screening for infectious diseases, cancers, genetic defects and other medically pertinent diagnostic information and are distributed in the United States and internationally. The Company operates through three segments: Enzo Life Sciences, Enzo Clinical Labs and Enzo Therapeutics. Enzo Life Sciences segment manufactures, develops and markets products and tools to clinical research, drug development and bioscience research customers around the world. Enzo Clinical Labs segment provides diagnostic services to the healthcare community. Enzo Therapeutics segment conducts research and development activities for therapeutic drug candidates.
Company Growth (employees)
Type
Public
HQ
New York, US
Founded
1976
Size (employees)
446 (est)
Website
enzo.com
Enzo Biochem was founded in 1976 and is headquartered in New York, US

Enzo Biochem Office Locations

Enzo Biochem has an office in New York
New York, US (HQ)
527 Madison Ave

Enzo Biochem Data and Metrics

Enzo Biochem Financial Metrics

Enzo Biochem's revenue was reported to be $102.8 m in FY, 2016 which is a 5% increase from the previous period.
Numbers are in $, USD

Revenue (FY, 2016)

102.8 m

Revenue growth (FY, 2015 - FY, 2016), %

5%

Net income (FY, 2016)

45.3 m

EBIT (FY, 2016)

47 m

Market capitalization (22-Jun-2017)

511.4 m

Closing share price (22-Jun-2017)

11.1

Cash (31-Dec-2016)

67.8 m
Enzo Biochem's current market capitalization is $511.4 m.
FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

93.7 m95.9 m97.6 m102.8 m

Revenue growth, %

2%2%5%

Operating expense total

112.7 m106.1 m98.8 m55.8 m

EBIT

(19 m)(10.2 m)(1.2 m)47 m

EBIT margin, %

(20%)(11%)(1%)46%

Interest expense

54 k208 k245 k136 k

Pre tax profit

(18.9 m)(9.9 m)(2.3 m)46.5 m

Income tax expense

(712 k)72 k(7 k)1.2 m

Net Income

(18.2 m)(10 m)(2.3 m)45.3 m
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

9 m17.5 m18.1 m67.8 m

Accounts Receivable

12.3 m12.5 m6.7 m6.7 m

Inventories

8.8 m8.7 m7.4 m7 m

Current Assets

32.6 m40.7 m46.5 m91.4 m

PP&E

8.6 m7.7 m7.9 m8.2 m

Goodwill

7.5 m7.5 m7.5 m7.5 m

Total Assets

59 m64.4 m68.4 m111.8 m

Current Liabilities

23.9 m25 m24 m20.6 m

Additional Paid-in Capital

304.3 m317.2 m325 m326.3 m

Retained Earnings

(272.4 m)(282.4 m)(284.7 m)(239.4 m)

Total Equity

34.1 m37 m42.6 m89.6 m

Financial Leverage

1.7 x1.7 x1.6 x1.2 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(18.2 m)(10 m)(2.3 m)45.3 m

Accounts Receivable

(2.6 m)(3.2 m)(2 m)(4.8 m)

Inventories

60 k159 k1.2 m466 k

Cash From Operating Activities

(10 m)(1.7 m)(3.7 m)53.1 m

Capital Expenditures

(988 k)(838 k)(1.8 m)(1.5 m)

Cash From Investing Activities

(971 k)(833 k)(1.8 m)(1.5 m)

Cash From Financing Activities

4.8 m10.9 m6.2 m(1.9 m)

Free Cash Flow

(11 m)(2.5 m)(5.5 m)51.6 m
Numbers are in $, USDY, 2016

Revenue/Employee

232 k

Financial Leverage

1.2 x

Enzo Biochem Operating Metrics

Enzo Biochem's Facilities was reported to be 2 in FY, 2016
FY, 2016

Patents Issued

314

Patents Pending

146

Facilities

2

Enzo Biochem Market Value History

Enzo Biochem Revenue Breakdown

Enzo Biochem Company Life and Culture

You may also be interested in